Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: betty moyers who wrote (20825)	4/20/1999 7:45:00 AM
From: John M. Gelnieau	Respond to of 23519

Look Out Viagra! Safe New Alternative Taps into Market! April 20, 1999 07:04 AM SAN RAMON, Calif.--(BW HealthWire)--April 20, 1999--Although Erogen, Inc. has not yet formally begun the marketing of its formulas, there are very few people who have not yet heard of Erogenex or Ex22 as it is also known. Erogenex is a non-prescription product that improves sexual performance and increases libido. There are two Erogenex Formulas, one for men, and one formulated specifically for women. There has been a lot of excitement surrounding Erogenex and its results, as it seems to be a safe alternative for those (both men and women) who suffer from "sexual dissatisfaction." Now it seems Erogen has even more cause for excitement. Although at this time Erogen will not disclose which company, a spokesperson has revealed that a very substantial distribution contract has just been signed with a large organization in Europe. Discussions are also being held with a U.S. Corporation that is interested in taking over all of the distribution and marketing of the Erogenex Formulas. To top it all off, Erogen, Inc. has just finalized an extensive internet marketing deal with one of the top up and coming internet companies, World Dot Com, Inc. With all of this news, and rumors of Erogen going public, it is easy to see why Erogen has had to hire telephone answering services to handle the overwhelming number of telephone calls they receive on a daily basis. Due to the fact that Erogenex is non-prescription and seems to have no negative side effects, Erogen has been able to tap in to a large segment of the market dominated mainly by Pfizer PFE . But Erogen, Inc. is not the only company trying to tap into this substantial market; Zonagen ZONA , Icos Corp ICOS , Tap Holdings, and Bio Technology General BTGC are all working on rival treatments, and Pentech Pharmaceuticals of Wheeling III has a drug in late-stage testing. Vivus, Inc. VVUS has a topical treatment called Muse, Macrochem Corp MCHM also has a topical, while Indianapolis-based Eli-Lilly LLY , and New York-based Bristol-Myers Squibb Co. BMY are both looking to make drugs from scratch through partnerships or from drugs now slated for other uses. All of these companies' products are prescription-only; one of the things that stand out about the Erogenex formulas is that they are available over the counter without a prescription. Another thing that stands out with Erogenex is the formula specifically for women. A recent Wall Street Journal article mentions Erogen, Inc. as one of the only companies with a formula for women.